Literature DB >> 26232350

Reliability of thromboelastometry for detecting the safe coagulation threshold in patients taking acenocoumarol after elective heart valve replacement.

Annabel Blasi1, Guido Muñoz2, Ines de Soto3, Ricard Mellado4, Pilar Taura5, Jose Rios6, Jaume Balust7, Joan Beltran8.   

Abstract

BACKGROUND: Reversal of anticoagulation can be needed in patients undergoing heart valve surgery. ROTEM® has been correlated with international normalized ratio (INR) in patients on warfarin but not with patients on acenocoumarol. This study investigates the reliability of ROTEM® for detecting INR values below the 1.5 threshold in patients on acenocoumarol therapy.
MATERIAL AND METHODS: Patients on oral anticoagulation with acenocoumarol after elective heart valve replacement were prospectively included in the study. INR and the ROTEM® were measured simultaneously. ROTEM® parameters included coagulation time, clot formation time, alpha angle, and maximal clot firmness after tissue factor activation (EXTEM). Concordance between INR and ROTEM® was analyzed by Lin's concordance coefficient (LCC) and the correlation with Spearman's rho.
RESULTS: Fifty-four consecutive patients (40 female; median age 67years) were included. Clotting time (CT) was the parameter that best correlated with INR (r=0.81, p<0,001), and LCC was substantial (0.67). CT was able to predict INR values above or below 1.5: area under curve=0.998. CT≥84seconds, corresponding to a cut-off for likelihood ratio (LR+)=5, had a sensitivity and specificity of 100% and 80%, respectively, to detect an INR below 1.5. For the same INR threshold, CT≥84seconds had a predictive positive value of 92.9% and a predictive negative value of 100%.
CONCLUSION: Our preliminary results suggest that CT≥84seconds in the EXTEM ROTEM® test is a feasible method for predicting an insufficient reversion of oral anticoagulant therapy in patients taking acenocoumarol after elective heart valve surgery.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  acenocumarol; thromboelastometry

Mesh:

Substances:

Year:  2015        PMID: 26232350     DOI: 10.1016/j.thromres.2015.07.003

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Characteristics of pulmonary infection after mitral valve repair in patients with metabolic syndrome and its relationship with blood pressure, blood glucose and blood lipid.

Authors:  Peng Xiao; Wei Song; Zhe Han
Journal:  Exp Ther Med       Date:  2018-10-09       Impact factor: 2.447

2.  Thromboelastometric evaluation of coagulation profiles of cold-stored autologous whole blood: A prospective observational study.

Authors:  Shihoko Iwata; Yuji Hirasaki; Minoru Nomura; Makoto Ozaki
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management.

Authors:  Klaus Görlinger; Antonio Pérez-Ferrer; Daniel Dirkmann; Fuat Saner; Marc Maegele; Ángel Augusto Pérez Calatayud; Tae-Yop Kim
Journal:  Korean J Anesthesiol       Date:  2019-05-17

Review 4.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

5.  Emergency Surgery in a Critically Ill Patient with Major Drug-Induced Bleeding and Severe Ischaemic Heart Failure.

Authors:  Dana Tomescu; Mihai Popescu
Journal:  J Crit Care Med (Targu Mures)       Date:  2017-02-18

6.  [Monitoring of coagulation by intraoperative thromboelastometry of liver transplantation in a patient using warfarin - case report].

Authors:  José Carlos Rodrigues Nascimento; David Silveira Marinho; Rodrigo Dornfeld Escalante; Bodiyabaduge Emmanuel M Daya Pereira Junior; Cristiane Gurgel Lopes; Rogean Rodrigues Nunes
Journal:  Braz J Anesthesiol       Date:  2018-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.